 Connection
Eric Wu to Neoplasm Metastasis
This is a "connection" page, showing publications Eric Wu has written about Neoplasm Metastasis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.385 |
|
|
|
-
Gu?rin A, Hao Y, Tang D, Peeples M, Fang A, Kageleiry A, Koo V, Li N, Wu EQ. Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study. Expert Opin Pharmacother. 2016 Jun; 17(9):1189-96.
Score: 0.113
-
Lin PL, Hao Y, Xie J, Li N, Zhong Y, Zhou Z, Signorovitch JE, Wu EQ. Physician experiences and preferences in the treatment of HR+/HER2- metastatic breast cancer in the United States: a?physician survey. Cancer Med. 2016 Feb; 5(2):209-20.
Score: 0.110
-
Kim Le T, Winfree KB, Yang H, Marynchenko M, Yu AP, Frois C, Wu EQ. Treatment patterns and economic burden of metastatic and recurrent locally-advanced head and neck cancer patients. J Med Econ. 2012; 15(4):786-95.
Score: 0.086
-
Hao Y, Li N, Fang AP, Koo V, Peeples M, Kageleiry A, Wu EQ, Gu?rin A. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy. Adv Ther. 2016 06; 33(6):983-97.
Score: 0.028
-
Li N, Hao Y, Koo V, Fang A, Peeples M, Kageleiry A, Wu EQ, Gu?rin A. Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis. J Med Econ. 2016; 19(4):414-23.
Score: 0.028
-
Yang H, Yu AP, Wu EQ, Yim YM, Yu E. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer. J Med Econ. 2011; 14(5):542-52.
Score: 0.020
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|